IMRX

Immuneering Corporation Class A Common Stock

5.07

USD

IMRX Earnings Reports

Positive Surprise Ratio

IMRX beat 14 of 19 last estimates.

74%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Immuneering Corporation Class A Common Stock earnings per share and revenue

On Mar 06, 2026, IMRX reported earnings of -0.18 USD per share (EPS) for Q4 25, beating the estimate of -0.31 USD, resulting in a 43.68% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.03% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Immuneering Corporation Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Immuneering Corporation Class A Common Stock reported EPS of -$0.18, beating estimates by 43.68%, and revenue of $0.00, 0% as expectations.

How did the market react to Immuneering Corporation Class A Common Stock's Q4 2025 earnings?

The stock price moved up 7.03%, changed from $4.98 before the earnings release to $5.33 the day after.

When is Immuneering Corporation Class A Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Immuneering Corporation Class A Common Stock's next earnings report?

Based on -- analysts, Immuneering Corporation Class A Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.